- All
- 2024/05/10
- 2024/05/11
- All
- Main Venue (DongFang 1 Ballroom 3F )
- Sub-Venue1（FuYue 2 Ballroom 3F）
- Sub-Venue2（FuYue 3 Ballroom 3F）
- Sub-Venue3（MingZhu Ballroom 3F）
- Sub-Venue4（No.8 Conference Room 3F）
- Sub-Venue5（No.9 Conference Room 3F）
2024/05/11
Sub-Venue5（No.9 Conference Room 3F）
| 1 | 08:30-08:40 | Oral Presentation |
Acromegaly presented with acne vulgaris: A retrospective study with 123 cases |
|
||||
| 2 | 08:40-08:50 | Oral Presentation |
Parental Awareness of Moisturizing Habits of Chinese Children with Atopic Dermatitis: A Multi-Center, Cross-Sectional Study |
|
||||
| 3 | 08:50-09:00 | Oral Presentation |
Efficacy and Safety of Abrocitinib in Asian Patients With Moderate-to-Severe Atopic Dermatitis |
|
||||
| 4 | 09:00-09:10 | Oral Presentation |
Intradermal Botulinum Toxin A Injection for Scalp Sebum Secretion Regulation: a Multi-center, Randomized, Double-blinded, Placebo-controlled, Prospective Study in Chinese Subjects |
|
||||
| 5 | 09:10-09:20 | Oral Presentation |
An open-label, multicenter phase 2 study of HLX07 monotherapy in the treatment of advanced cutaneous squamous cell carcinoma |
|
||||
| 6 | 09:20-09:30 | Oral Presentation |
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Plaque Psoriasis: Body Surface Area Involvement and Psoriasis Area and Severity Index Outcomes in the Phase 3 POETYK PSO-3 Trial |
|
||||
| 7 | 09:30-09:40 | Oral Presentation |
Comprehensive analysis of effectiveness and cost-effectiveness of treatments for psoriasis integrating clinician- and patient-reported outcomes: a cohort study from SPEECH |
|
||||
| 8 | 09:40-09:50 | Oral Presentation |
Omalizumab on Chronic Spontaneous Urticaria: A Real-World Study on Effectiveness, Safety and Predictors of Treatment Outcome |
|
||||
| 9 | 09:50-10:00 | Oral Presentation |
The implications of CCL19/21-CCR7 axis in Hidradenitis Suppurativa |
|
||||
| 1 | 10:30-10:38 | Oral Presentation |
Dupilumab in combination with JAK inhibitor for refractory moderate-to-severe atopic dermatitis |
|
||||
| 2 | 10:38-10:46 | Oral Presentation |
Naloxone protects against TWEAK-induced apoptolysis in pemphigus |
|
||||
| 3 | 10:46-10:54 | Oral Presentation |
Liposomes loaded with 5-fluorouracil can improve the efficacy in pathological scars |
|
||||
| 4 | 10:54-11:02 | Oral Presentation |
Case series: Clinical and pathological association of a group of cutaneous aggressive lymphomas |
|
||||
| 5 | 11:02-11:10 | Oral Presentation |
Treatment of severe alopecia areata in children with baricitinib: A retrospective review of 31 patients |
|
||||
| 6 | 11:10-11:18 | Oral Presentation |
PDT combined with localized sclerotherapy successfully treated perineal hemangioma |
|
||||
| 7 | 11:18-11:26 | Oral Presentation |
Treatment With Selumetinib for Café-au-Lait Macules and Plexiform Neurofibroma in Pediatric Patients With Neurofibromatosis Type 1 |
|
||||
| 8 | 11:26-11:34 | Oral Presentation |
Analysis of clinical characteristics of juvenile localized scleroderma |
|
||||
| 9 | 11:34-11:42 | Oral Presentation |
Case Series: Efficacy and safety of Spesolimab in pediatric GPP |
|
||||
| 10 | 11:42-11:50 | Oral Presentation |
High-Frequency Ultrasound Combined with Mohs Micrographic Surgery for the Treatment of Dermatofibrosarcoma Protuberans: Case Report and Systematic Review |
|
||||
| 11 | 11:50-11:58 | Oral Presentation |
Itraconazole as a novel therapy for recalcitrant pyoderma gangrenosum |
|
||||
| 12 | 11:58-12:06 | Oral Presentation |
Trem2 acts as a non-classical receptor of IL-4 to promote diabetic wound healing |
|
||||